Saliogen Therapeutics, Inc.
Records under this name other than patents Saliogen Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Saliogen Therapeutics, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,542,528 | Transposition-Based Therapies now held by Blue Marlin Therapeutics, Inc. In force · High confidence | In force | High confidence | |
| US 11,993,784 | Transposition-Based Therapies now held by Blue Marlin Therapeutics, Inc. In force · High confidence | In force | High confidence | |
| 17/922,118 | Compositions and Methods for Treatment of Familial Hypercholesterolemia and Elevated Low-Density Lipoprotein Cholesterol Abandoned Abandoned Apr 1, 2026 | Abandoned | Abandoned Apr 1, 2026 | |
| 17/922,119 | Compositions and Methods for Treatment of Inherited Macular Degeneration now held by Blue Marlin Therapeutics, Inc. Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/037,937 | Mammalian Mobile Element Compositions, Systems and Therapeutic Applications now held by Blue Marlin Therapeutics, Inc. Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/058,486 | Transposition-Based Therapies now held by Blue Marlin Therapeutics, Inc. Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/704,658 | Manufacturing of Stem Cells Abandoned Abandoned Jun 30, 2025 | Abandoned | Abandoned Jun 30, 2025 | |
| 18/706,018 | Immune Cells with Chimeric Antigen Receptors or Chimeric Autoantibody Receptors now held by Blue Marlin Therapeutics, Inc. Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/706,118 | Mobile Elements and Chimeric Constructs Thereof now held by Blue Marlin Therapeutics, Inc. Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/706,257 | Transposable Mobile Elements with Enhanced Genomic Site Selection now held by University of Hawaii Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. |